Bausch + Lomb Bolsters Eye Health Portfolio with B Vitamin Research
Event summary
- A narrative review published in *Ophthalmology and Therapy* highlights the potential of B vitamins in reducing the risk and progression of Age-Related Macular Degeneration (AMD).
- The review synthesizes data from over 20 human studies involving nearly 30,000 individuals, spanning two decades of research.
- Bausch + Lomb is planning a long-term clinical trial to evaluate a new B-vitamin complex formulation.
- PreserVision AREDS3 eye vitamins, enhanced with B vitamins, are now available in the U.S. and expected to be widely available by June 2026.
The big picture
Bausch + Lomb's move to integrate B vitamins into its PreserVision line reflects a broader trend in the eye health market towards preventative and nutritional interventions for age-related conditions. The company is capitalizing on growing consumer interest in natural supplements and personalized healthcare solutions, particularly as the aging population expands. This research provides a potential competitive advantage, but also introduces execution risk associated with clinical trial outcomes and potential regulatory challenges.
What we're watching
- Clinical Validation
- The success of the planned long-term clinical trial will be crucial in substantiating the efficacy claims and driving adoption of the B-vitamin enhanced PreserVision formula.
- Regulatory Scrutiny
- Increased focus on nutritional supplement claims may lead to greater regulatory scrutiny of Bausch + Lomb's marketing and labeling practices for PreserVision.
- Competitive Response
- Other eye health companies will likely respond to Bausch + Lomb’s findings by exploring their own B vitamin formulations, potentially intensifying competition in the nutritional supplement space.
Related topics